HRP20110348T1 - Imunološke primjene imunomodulatornih spojeva za cjepivo i za liječenje infektivnih bolesti - Google Patents
Imunološke primjene imunomodulatornih spojeva za cjepivo i za liječenje infektivnih bolesti Download PDFInfo
- Publication number
- HRP20110348T1 HRP20110348T1 HR20110348T HRP20110348T HRP20110348T1 HR P20110348 T1 HRP20110348 T1 HR P20110348T1 HR 20110348 T HR20110348 T HR 20110348T HR P20110348 T HRP20110348 T HR P20110348T HR P20110348 T1 HRP20110348 T1 HR P20110348T1
- Authority
- HR
- Croatia
- Prior art keywords
- vaccine
- administration
- compound
- subject
- days
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 19
- 229960005486 vaccine Drugs 0.000 title claims 23
- 201000010099 disease Diseases 0.000 title claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 2
- 230000002924 anti-infective effect Effects 0.000 title 1
- 230000001900 immune effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 230000028993 immune response Effects 0.000 claims abstract 5
- 230000002708 enhancing effect Effects 0.000 claims abstract 2
- 208000035473 Communicable disease Diseases 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 3
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 3
- 241000894006 Bacteria Species 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 229940029030 dendritic cell vaccine Drugs 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 229940023041 peptide vaccine Drugs 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract 2
- 239000013566 allergen Substances 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Spoj 4-(amino)-2-(2,6-diokso(3-piperidil))-izoindolin-1,3-dion ili 3-(4-amino-1-okso-1,3-dihidroizoindol-2-il)-piperidin-2,6-dion, naznačen time što se koristi za primjenu za izazivanje pojačanog imunog odgovora na cjepivo kod subjekta, pri čemu je spoj oblikovan za primjenu subjektu prije davanja cjepiva tom subjektu. Patent sadrži još 10 patentnih zahtjeva.
Claims (11)
1. Spoj 4-(amino)-2-(2,6-diokso(3-piperidil))-izoindolin-1,3-dion ili 3-(4-amino-1-okso-1,3-dihidroizoindol-2-il)-piperidin-2,6-dion, naznačen time što se koristi za primjenu za izazivanje pojačanog imunog odgovora na cjepivo kod subjekta, pri čemu je spoj oblikovan za primjenu subjektu prije davanja cjepiva tom subjektu.
2. Spoj za primjenu prema zahtjevu 1, naznačen time što je cjepivo jedno od cjepiva navedenih u sljedećoj tablici:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
3. Spoj 4-(amino)-2-(2,6-diokso(3-piperidil))-izoindolin-1,3-dion ili 3-(4-amino-1-okso-1,3-dihidroizoindol-2-il)-piperidin-2,6-dion, naznačen time što se koristi za primjenu za pojačanje imunog odgovora na cjepivo protiv tumora kod subjekta, pri čemu je spoj oblikovan za davanje subjektu prije davanja spomenutog cjepiva tom subjektu.
4. Spoj za primjenu prema zahtjevu 3, naznačen time što spomenuto cjepivo predstavlja cjepivo protiv sarkoma, karcinoma, melanoma, limfoma i leukemije.
5. Spoj za primjenu prema zahtjevu 3, naznačen time što je cjepivo antigenski modificirano dendritno-stanično cjepivo, peptidno cjepivo, cjepivo s cijelim tumorskim stanicama ili cjepivo s viralnim vektorom.
6. Spoj 4-(amino)-2-(2,6-diokso(3-piperidil))-izoindolin-1,3-dion ili 3-(4-amino-1-okso-1,3-dihidroizoindol-2-il)-piperidin-2,6-dion, naznačen time što se koristi za primjenu za pojačanje imunog odgovora na cjepivo protiv infektivne bolesti kod subjekta, pri čemu je spoj oblikovan za davanje subjektu prije davanja spomenutog cjepiva tom subjektu.
7. Spoj za primjenu prema zahtjevu 6, naznačen time što je infektivna bolest bolest izazvana virusom, bakterijom, gljivicom i parazitom.
8. Spoj za primjenu prema zahtjevu 7, naznačen time što je infektivna bolest hepatitis B.
9. Spoj za primjenu prema zahtjevu 1, 3, ili 6, naznačen time što je spoj oblikovan za davanje od 10 dana do 12 sati prije davanja cjepiva, od 7 dana do 12 sati prije davanja cjepiva, od 5 dana do 1 dan prije davanja cjepiva, ili od 3 dana do 1 dan prije davanja cjepiva.
10. Spoj za primjenu prema zahtjevu 1, 3 ili 6, naznačen time što je spoj dalje oblikovan za drugo davanje poslije davanja cjepiva.
11. Spoj za primjenu prema zahtjevu 10, naznačen time što je spoj oblikovan za davanje od 12 sati do 10 dana poslije davanja cjepiva, od 12 sati do 7 dana poslije davanja cjepiva, od 1 dan do 5 dana poslije davanja cjepiva, ili od 1 dan do 3 dana poslije davanja cjepiva.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71282305P | 2005-09-01 | 2005-09-01 | |
| PCT/US2006/034271 WO2007028047A2 (en) | 2005-09-01 | 2006-08-31 | Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110348T1 true HRP20110348T1 (hr) | 2011-07-31 |
Family
ID=37806889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110348T HRP20110348T1 (hr) | 2005-09-01 | 2011-05-10 | Imunološke primjene imunomodulatornih spojeva za cjepivo i za liječenje infektivnih bolesti |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8715677B2 (hr) |
| EP (2) | EP2301535B1 (hr) |
| JP (2) | JP2009507030A (hr) |
| AT (1) | ATE499112T1 (hr) |
| CA (1) | CA2621136C (hr) |
| CY (1) | CY1112325T1 (hr) |
| DE (1) | DE602006020300D1 (hr) |
| DK (1) | DK1928492T3 (hr) |
| ES (2) | ES2359162T3 (hr) |
| HR (1) | HRP20110348T1 (hr) |
| PL (1) | PL1928492T3 (hr) |
| RS (1) | RS51840B (hr) |
| SI (1) | SI1928492T1 (hr) |
| WO (1) | WO2007028047A2 (hr) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090068210A1 (en) * | 2007-07-09 | 2009-03-12 | Munshi Nikhil C | Immunotherapy for hematological malignancies |
| US9200253B1 (en) * | 2007-08-06 | 2015-12-01 | Anthrogenesis Corporation | Method of producing erythrocytes |
| NZ584425A (en) | 2007-09-26 | 2012-03-30 | Celgene Corp | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same |
| WO2009131730A2 (en) | 2008-01-31 | 2009-10-29 | University Of Iowa Research Foundation | IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS |
| US20090298882A1 (en) * | 2008-05-13 | 2009-12-03 | Muller George W | Thioxoisoindoline compounds and compositions comprising and methods of using the same |
| BRPI0919942B1 (pt) | 2008-10-29 | 2019-02-19 | Celgene Corporation | Composto, composição farmacêutica que o compreende e uso do referido composto |
| US20120053159A1 (en) | 2009-02-11 | 2012-03-01 | Muller George W | Isotopologues of lenalidomide |
| DK2391355T3 (en) | 2009-05-19 | 2017-02-27 | Celgene Corp | FORMULATIONS OF 4-AMINO-2- (2,6-DIOXOPIPERIDIN-3-YL) ISOINDOLIN-1,3-DION |
| AU2010333767A1 (en) | 2009-12-22 | 2012-07-05 | Celgene Corporation | (Methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PL3590949T3 (pl) | 2010-10-01 | 2022-08-29 | Modernatx, Inc. | Kwasy rybonukleinowe zawierające n1-metylo-pseudouracyle i ich zastosowania |
| CN103402980B (zh) | 2011-01-10 | 2016-06-29 | 细胞基因公司 | 作为pde4和/或细胞因子抑制剂的苯乙基砜异吲哚啉衍生物 |
| CA2867134C (en) | 2011-03-28 | 2019-05-07 | Sheila Dewitt | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US20140221427A1 (en) | 2011-06-22 | 2014-08-07 | Celgene Corporation | Isotopologues of pomalidomide |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2848493A1 (en) | 2011-09-14 | 2013-03-21 | Celgene Corporation | Formulations of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide |
| AU2012318752B2 (en) | 2011-10-03 | 2017-08-31 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| LT2791160T (lt) | 2011-12-16 | 2022-06-10 | Modernatx, Inc. | Modifikuotos mrnr sudėtys |
| PL2797581T3 (pl) | 2011-12-27 | 2020-10-05 | Amgen (Europe) GmbH | Formulacje (+)-2-[1-(3-etoksy-4-metoksy-fenylo)-2-metanosulfonylo-etylo]- 4acetyloaminoizoindolino-1,3-dionu |
| AU2013243951A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| EP3967323A3 (en) | 2012-06-06 | 2022-05-04 | Bionor Immuno AS | Hiv vaccine |
| TWI690322B (zh) * | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| JP6144355B2 (ja) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | 化学修飾ｍＲＮＡ |
| WO2014110558A1 (en) | 2013-01-14 | 2014-07-17 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| SG11201507759WA (en) | 2013-04-02 | 2015-10-29 | Celgene Corp | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
| EP2801364A1 (en) * | 2013-05-07 | 2014-11-12 | Centre Hospitalier Universitaire Vaudois (CHUV) | Salmonella strain for use in the treatment and/or prevention of cancer |
| EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| WO2015007337A1 (en) | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
| WO2016005508A1 (en) | 2014-07-11 | 2016-01-14 | Bionor Immuno As | Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids) |
| US20180140694A1 (en) | 2015-05-04 | 2018-05-24 | Bionor Immuno As | Dosage regimen for hiv vaccine |
| TWI727211B (zh) * | 2018-09-27 | 2021-05-11 | 大江生醫股份有限公司 | 紅菽草萃取物用於提升玻尿酸合成酶之基因表現量的用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2444713A1 (fr) | 1978-12-18 | 1980-07-18 | Pasteur Institut | Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant |
| EP0466813A4 (en) | 1989-04-05 | 1992-07-15 | Peter Y. S Fung | Active specific immunotherapy of adenocarcinomas producing immunosuppressive mucins |
| EP0621780A1 (en) | 1992-01-21 | 1994-11-02 | Immulogic Pharmaceutical Corporation | Methods for using histamine derivatives as immunomodulators and in immunotherapeutics |
| US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| US5728385A (en) * | 1993-08-12 | 1998-03-17 | Classen Immunotherapies, Inc. | Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| ES2529190T3 (es) | 1996-07-24 | 2015-02-17 | Celgene Corporation | 2-(2,6-dioxopiperidin-3-il)-ftalimidas sustituidas por amino para reducir los niveles de TNF-alfa |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5798368A (en) | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
| AU729247B2 (en) | 1996-08-12 | 2001-01-25 | Celgene Corporation | Novel immunotherapeutic agents and their use in the reduction of cytokine levels |
| US5955476A (en) | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
| US5874448A (en) | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
| JP4695259B2 (ja) | 1998-03-16 | 2011-06-08 | セルジーン コーポレイション | ２−（２，６−ジオキソピペリジン−３−イル）イソインドリン誘導体、その製剤および炎症性サイトカイン阻害剤としてのその使用 |
| EP1163219B1 (en) | 1999-03-18 | 2005-10-12 | Celgene Corporation | Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels |
| AU2593701A (en) * | 1999-12-21 | 2001-07-03 | Regents Of The University Of California, The | Method for preventing an anaphylactic reaction |
| AUPR030800A0 (en) * | 2000-09-22 | 2000-10-12 | Pharmalink International Limited | Immunomodulatory preparation |
| US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US20030129161A1 (en) | 2001-09-17 | 2003-07-10 | Hsien-Jue Chu | Interleukin-12 as a veterinary vaccine adjuvant |
| JP2005532296A (ja) * | 2002-04-19 | 2005-10-27 | エンドサイト，インコーポレイテッド | アジュバントにより増強される免疫療法 |
| EP2272512A1 (en) * | 2002-05-17 | 2011-01-12 | Celgene Corporation | Pharmaceutical compositions for treating cancer |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| CA2501940A1 (en) * | 2002-10-09 | 2004-04-22 | Tolerrx, Inc. | Molecules preferentially associated with effector t cells or regulatory t cells and methods of their use |
| WO2004078928A2 (en) * | 2003-02-28 | 2004-09-16 | The Johns Hopkins University | T cell regulation |
| US20050048054A1 (en) | 2003-07-11 | 2005-03-03 | Shino Hanabuchi | Lymphocytes; methods |
| US9713375B1 (en) | 2015-02-26 | 2017-07-25 | Brett Einar Rahm | Collapsible portable table |
-
2006
- 2006-08-31 AT AT06824878T patent/ATE499112T1/de active
- 2006-08-31 DK DK06824878.0T patent/DK1928492T3/da active
- 2006-08-31 ES ES06824878T patent/ES2359162T3/es active Active
- 2006-08-31 US US11/514,447 patent/US8715677B2/en not_active Expired - Fee Related
- 2006-08-31 DE DE602006020300T patent/DE602006020300D1/de active Active
- 2006-08-31 RS RS20110194A patent/RS51840B/en unknown
- 2006-08-31 WO PCT/US2006/034271 patent/WO2007028047A2/en active Application Filing
- 2006-08-31 CA CA2621136A patent/CA2621136C/en not_active Expired - Fee Related
- 2006-08-31 SI SI200631013T patent/SI1928492T1/sl unknown
- 2006-08-31 EP EP11151126.7A patent/EP2301535B1/en active Active
- 2006-08-31 PL PL06824878T patent/PL1928492T3/pl unknown
- 2006-08-31 EP EP06824878A patent/EP1928492B1/en active Active
- 2006-08-31 ES ES11151126.7T patent/ES2485316T3/es active Active
- 2006-08-31 JP JP2008529318A patent/JP2009507030A/ja not_active Withdrawn
-
2011
- 2011-04-13 CY CY20111100376T patent/CY1112325T1/el unknown
- 2011-05-10 HR HR20110348T patent/HRP20110348T1/hr unknown
-
2012
- 2012-04-02 US US13/437,739 patent/US20120190110A1/en not_active Abandoned
-
2013
- 2013-07-03 JP JP2013140191A patent/JP5796040B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2301535A1 (en) | 2011-03-30 |
| JP2013241424A (ja) | 2013-12-05 |
| WO2007028047A3 (en) | 2007-06-14 |
| JP2009507030A (ja) | 2009-02-19 |
| RS51840B (en) | 2012-02-29 |
| EP1928492B1 (en) | 2011-02-23 |
| EP2301535B1 (en) | 2014-05-28 |
| ES2359162T3 (es) | 2011-05-19 |
| ES2485316T3 (es) | 2014-08-13 |
| DK1928492T3 (da) | 2011-06-06 |
| SI1928492T1 (sl) | 2011-09-30 |
| WO2007028047A2 (en) | 2007-03-08 |
| CY1112325T1 (el) | 2015-12-09 |
| ATE499112T1 (de) | 2011-03-15 |
| CA2621136A1 (en) | 2007-03-08 |
| EP1928492A2 (en) | 2008-06-11 |
| JP5796040B2 (ja) | 2015-10-21 |
| US8715677B2 (en) | 2014-05-06 |
| PL1928492T3 (pl) | 2011-09-30 |
| CA2621136C (en) | 2014-10-14 |
| US20070048327A1 (en) | 2007-03-01 |
| DE602006020300D1 (de) | 2011-04-07 |
| US20120190110A1 (en) | 2012-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110348T1 (hr) | Imunološke primjene imunomodulatornih spojeva za cjepivo i za liječenje infektivnih bolesti | |
| Slifka et al. | Long-term humoral immunity against viruses: revisiting the issue of plasma cell longevity | |
| Alam et al. | CD4 T cell help is limiting and selective during the primary B cell response to influenza virus infection | |
| JP2009507030A5 (hr) | ||
| Yokokawa et al. | Induction of humoural and cellular immunity by immunisation with HCV particle vaccine in a non-human primate model | |
| DK1294893T3 (da) | Modifikation af hepatitis B-kerneantigen | |
| Van den Berg et al. | Non-responsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions | |
| CY1112572T1 (el) | Εμβολια γριπης που περιλαμβανουν συνδυασμους σωματιδιακων ανοσοενισχυτικων και ανοσοδιεγερτες | |
| Richards et al. | Recombinant HA-based vaccine outperforms split and subunit vaccines in elicitation of influenza-specific CD4 T cells and CD4 T cell-dependent antibody responses in humans | |
| BG98523A (en) | Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b | |
| ATE527281T1 (de) | Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte | |
| DK0528859T3 (da) | Oral vaccine, som omfatter antigen knyttet til overfladen af røde blodlegemer | |
| DE60121136D1 (de) | Proteasom-influenzavirus-impfstoffzusammensetzung | |
| US20090304735A1 (en) | Immunogenic Compositions | |
| NZ545048A (en) | Chimeric antigens for breaking host tolerance to foreign antigens | |
| HK1132934A1 (en) | Vaccine composition containing synthetic adjuvant | |
| IL130075A0 (en) | A vaccine for eliciting an immune response to an antigen in an animal | |
| Wagstaffe et al. | Vaccinating for natural killer cell effector functions | |
| CY1110744T1 (el) | Ανοσοδιεγερτικος συνδυασμος για την προφυλακτικη και θεραπευτικη αντιμετωπιση της ηπατιτιδας c | |
| Quattrocchi et al. | Co-inoculation of baculovirus and FMDV vaccine in mice, elicits very early protection against foot and mouth disease virus without interfering with long lasting immunity | |
| Julier et al. | Fibronectin EDA and CpG synergize to enhance antigen-specific Th1 and cytotoxic responses | |
| Aspord et al. | pDCs efficiently process synthetic long peptides to induce functional virus‐and tumour‐specific T‐cell responses | |
| Zhao et al. | Clearance of HBeAg and HBsAg of HBV in mice model by a recombinant HBV vaccine combined with GM-CSF and IFN-α as an effective therapeutic vaccine adjuvant | |
| TW200734463A (en) | Marked bovine viral diarrhea virus vaccines | |
| Kalia et al. | CD8+ T cells are crucial for humoral immunity establishment by SA14‐14‐2 live attenuated Japanese encephalitis vaccine in mice |